Beam Therapeutics Inc.
$31.19
▲
1.82%
2026-04-21 05:37:00
beamtx.com
NMS: BEAM
Explore Beam Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.2 B
Current Price
$31.19
52W High / Low
$36.44 / $15.35
Stock P/E
—
Book Value
$12.48
Dividend Yield
—
ROCE
-27.72%
ROE
-8.11%
Face Value
—
EPS
$-0.81
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
511
Beta
2.19
Debt / Equity
12.45
Current Ratio
13.09
Quick Ratio
13.09
Forward P/E
-6.25
Price / Sales
19.99
Enterprise Value
$1.63 B
EV / EBITDA
-4.52
EV / Revenue
11.69
Rating
Strong Buy
Target Price
$51.2
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tango Therapeutics, Inc. | $26.39 | — | $3.8 B | — | -29.52% | -37.23% | $26.81 / $1.03 | $2.55 |
| 2. | Cullinan Therapeutics, Inc. | $14.52 | — | $911.52 M | — | -58.85% | -44.02% | $16.74 / $5.68 | $6.79 |
| 3. | ABVC BioPharma, Inc. | $1.3 | — | $33.58 M | — | -48% | -1.19% | $5.48 / $0.81 | $0.46 |
| 4. | Roivant Sciences Ltd. | $29.41 | — | $21.16 B | — | -21.06% | -19.14% | $30.33 / $10.01 | $6.02 |
| 5. | Galectin Therapeutics Inc. | $2.29 | — | $156.67 M | — | -174.62% | 26.9% | $7.13 / $1.21 | $-1.97 |
| 6. | Revolution Medicines, Inc. | $143.09 | — | $30.24 B | — | -57.28% | -58.07% | $155.7 / $34 | $8.28 |
| 7. | ArriVent BioPharma, Inc. | $31.39 | — | $1.31 B | — | -57.79% | -58.88% | $30.72 / $16.1 | $7.24 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 114.11 M | 9.7 M | 8.47 M | 7.47 M | 30.07 M | — |
| Operating Profit | -17.45 M | -126.81 M | -120.15 M | -119.29 M | -100.04 M | — |
| Net Profit | 244.3 M | -112.73 M | -102.29 M | -109.27 M | -90.35 M | — |
| EPS in Rs | 2.4 | -1.11 | -1 | -1.07 | -0.89 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 139.74 M | 63.52 M | 377.71 M | 60.92 M |
| Operating Profit | -383.69 M | -415.57 M | -176.49 M | -338.48 M |
| Net Profit | -79.99 M | -376.74 M | -132.53 M | -289.09 M |
| EPS in Rs | -0.79 | -3.7 | -1.3 | -2.84 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.48 B | 1.1 B | 1.46 B | 1.34 B |
| Total Liabilities | 242.82 M | 370.28 M | 478.38 M | 608.24 M |
| Equity | 1.24 B | 733.54 M | 981.33 M | 733.47 M |
| Current Assets | 1.27 B | 878.15 M | 1.21 B | 1.09 B |
| Current Liabilities | 96.94 M | 182.07 M | 205.56 M | 223.59 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -345.1 M | -347.25 M | -149.19 M | 22.53 M |
| Investing CF | -121.44 M | 185.01 M | 71.84 M | -461.34 M |
| Financing CF | 478.05 M | 7.74 M | 276.45 M | 111.59 M |
| Free CF | -360.05 M | -356.19 M | -182.93 M | -26.42 M |
| Capex | -14.95 M | -8.95 M | -33.73 M | -48.95 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -83.18% | 520.01% | — | — |
| Earnings Growth % | -184.28% | 54.16% | — | — |
| Profit Margin % | -593.13% | -35.09% | -474.54% | — |
| Operating Margin % | -654.25% | -46.73% | -555.61% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -619.73% | -41.43% | -518.55% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.